LFG
TSHA icon

Larson Financial Group’s Taysha Gene Therapies TSHA Stock Holding History

Larson Financial Group’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.19K Buy
469
+341
+266% +$2.02K ﹤0.01% 2952
2026
Q1 		$572 Buy
+128
New +$595 ﹤0.01% 3292

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Larson Financial Group's TSHA Position: Q2 2026 in Review

Larson Financial Group increased its Taysha Gene Therapies (TSHA) stake by 266% in Q2 2026, buying an estimated $2.02K and bringing the position to 469 shares worth $3.19K. The position accounts for ﹤0.01% of the portfolio, ranked #2952.

Larson Financial Group first reported a position in TSHA in Q1 2026 and has held it in 2 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Larson Financial Group held 469 shares of Taysha Gene Therapies worth $3.19K as of Q2 2026.
  • Larson Financial Group bought 341 Taysha Gene Therapies shares in Q2 2026, an estimated $2.02K.
  • Taysha Gene Therapies made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #2952 holding.
  • Larson Financial Group first reported a position in Taysha Gene Therapies in Q1 2026 and has held it in 2 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.